广州安必平医药科技股份有限公司 关于 2025 年度"提质增效重回报"专项行动方案的 半年度评估报告 为积极践行"以投资者为本"的上市公司发展理念，响应上海证券交易所《关 于开展沪市公司"提质增效重回报"专项行动的倡议》，广州安必平医药科技股 份有限公司（以下简称"公司"）于 2025 年 4 月发布了《2025 年度"提质增效 重回报"行动方案》。公司根据行动方案内容，积极开展和落实各项工作，现将 一、 聚焦病理诊断领域，推动病理"四化" 公司业务主要集中在医院病理科，经过多年发展已经覆盖了诊断试剂及原料、 制片读片自动化一体机、辅助诊断人工智能软件等全产业链条。搭建完成液基细 胞学（LBP） 、聚合酶链式反应（PCR）、免疫组织化学（IHC）和荧光原位杂交（FISH） 四大病理诊断方法学，是国内方法学最全的病理诊断公司，并在各产品线进行"试 剂+自动化设备+数字化产品+人工智能辅助诊断系统"的病理诊断数智化升级。 报告期内，公司新获批 12 项诊断相关注册/备案证，截至报告期末，拥有国内超 现归属于母公司所有者的净利润-1,249.85 万元，同比下降 176.38%。受内外部 因素影响，上半年公司经营层 ...

Core Viewpoint - The report highlights a significant decline in the company's financial performance for the first half of 2025, primarily due to the impact of centralized procurement policies on the HPV product line, leading to a 30.11% decrease in revenue and a 176.38% drop in net profit compared to the same period last year [2][3][11]. Company Overview and Financial Indicators - Guangzhou Anbiping Medical Technology Co., Ltd. is focused on the pathology diagnosis industry, offering a comprehensive range of diagnostic reagents and automated equipment [2][4]. - The company reported a total revenue of approximately 159.40 million yuan, down from 228.07 million yuan in the same period last year, marking a 30.11% decrease [3][11]. - The total profit for the period was -18.49 million yuan, a decline of 333.51% compared to the previous year's profit of 7.92 million yuan [3][11]. - The net profit attributable to shareholders was -12.50 million yuan, down 176.38% from 16.36 million yuan in the previous year [3][11]. - The company’s net assets decreased by 1.94% to approximately 1.23 billion yuan compared to the end of the previous year [3][11]. Business Operations and Market Position - The company operates in the in vitro diagnostics (IVD) sector, specifically in pathology diagnosis, which is a critical area for cancer screening and diagnosis [8][11]. - The company has developed a full range of pathology diagnostic methods, including liquid-based cytology (LBP), polymerase chain reaction (PCR), immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH) [4][8]. - The company has received 12 new diagnostic-related registrations/approvals during the reporting period, bringing its total to over 600 [4][5]. - The company has established a marketing network covering over 2,500 medical institutions in China and has begun expanding into international markets [5][11]. Research and Development - The company invested approximately 21.25 million yuan in R&D, representing 13.33% of its revenue, focusing on AI applications in diagnostics and automation of pathology processes [12][14]. - The company has made significant advancements in AI-assisted diagnostic products, with a sensitivity of 85.8% for its cervical cytology AI, significantly higher than the 71.7% sensitivity of primary pathologists [14][22]. - The company has developed a fully automated liquid-based cytology workstation, XPro90, which streamlines the diagnostic process [20][21]. Industry Context - The pathology diagnosis industry is experiencing growth due to increasing cancer incidence rates, with over 4.82 million new cancer cases reported in China in 2022 [8][11]. - The company is positioned to benefit from national policies aimed at enhancing healthcare resource distribution and improving cancer screening and treatment [11][19]. - The company is actively involved in building pathology capabilities in collaboration with hospitals, focusing on personalized solutions for different healthcare settings [13][21].